Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 34555333

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2021 Oct 9
First author
Felip E

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Oct 9;398(10308):1281-1283. doi: 10.1016/S0140-6736(21)02100-0.
    note
    Source null
    related pmid
    34555332
    relationship
    Comment in
  2. citation
    Lancet. 2021 Nov 6;398(10312):1686. doi: 10.1016/S0140-6736(21)02135-8.
    note
    Source null
    related pmid
    34563273
    relationship
    Erratum in
  3. citation
    Nat Rev Clin Oncol. 2022 Jan;19(1):7-8. doi: 10.1038/s41571-021-00574-1.
    note
    Source null
    related pmid
    34707252
    relationship
    Comment in

Authors and identifiers

  1. name
    Felip E
    type
    Author
  2. name
    Altorki N
    type
    Author
  3. name
    Zhou C
    type
    Author
  4. name
    Csőszi T
    type
    Author
  5. name
    Vynnychenko I
    type
    Author
  6. name
    Goloborodko O
    type
    Author
  7. name
    Luft A
    type
    Author
  8. name
    Akopov A
    type
    Author
  9. name
    Martinez-Marti A
    type
    Author
  10. name
    Kenmotsu H
    type
    Author
  11. name
    Chen YM
    type
    Author
  12. name
    Chella A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Felip E
    type
    Author
  2. name
    Altorki N
    type
    Author
  3. name
    Zhou C
    type
    Author
  4. name
    Csőszi T
    type
    Author
  5. name
    Vynnychenko I
    type
    Author
  6. name
    Goloborodko O
    type
    Author
  7. name
    Luft A
    type
    Author
  8. name
    Akopov A
    type
    Author
  9. name
    Martinez-Marti A
    type
    Author
  10. name
    Kenmotsu H
    type
    Author
  11. name
    Chen YM
    type
    Author
  12. name
    Chella A
    type
    Author
bibliography ids
  1. nci-bib-ee7f26f222ab5d1ba329bf63
book metadata
content sha256
21cdf018e124038c6034b77666ff60e0a2b2f5db84f4ccc8a14e5db50dfbb37f
document type
citation
dois
  1. 10.1016/S0140-6736(21)02098-5
electronic publication date
display
2021 Sep 20
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34555333
immutable id
pubmed:34555333@21cdf018e124038c6034b77666ff60e0a2b2f5db84f4ccc8a14e5db50dfbb37f
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10308
name
Lancet (London, England)
nlm unique id
2985213R
pages
1344-1357
volume
398
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Oct 9;398(10308):1281-1283. doi: 10.1016/S0140-6736(21)02100-0.
    note
    Source null
    related pmid
    34555332
    relationship
    Comment in
  2. citation
    Lancet. 2021 Nov 6;398(10312):1686. doi: 10.1016/S0140-6736(21)02135-8.
    note
    Source null
    related pmid
    34563273
    relationship
    Erratum in
  3. citation
    Nat Rev Clin Oncol. 2022 Jan;19(1):7-8. doi: 10.1038/s41571-021-00574-1.
    note
    Source null
    related pmid
    34707252
    relationship
    Comment in
outcomes validated
false
pmid
34555333
provenance
batch id
192b6392c165c6b06274
provider
NCBI PubMed ESummary
record sha256
50325fb3fc18d58eb79740b65e47cc5b2de3f9338ccc15942769e6f1ae1bd672
response sha256
7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
retrieved at
2026-09-09T23:48:02.713075+00:00
publication date
display
2021 Oct 9
precision
day
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34555333/
title
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

Preserved source evidence · Independent clinical review pending · Not medical advice